1. At a Glance – The ₹22,298 Cr Oncology Rocket
₹8,919 per share.
Market cap: ₹22,298 Cr.
Stock P/E: 107.
ROCE: 33.4%.
ROE: 23.6%.
Debt to equity: 0.04.
Latest quarter sales: ₹612 Cr.
Latest quarter PAT: ₹31.6 Cr.
3-month return: -2.42%.
Meet AstraZeneca Pharma India Ltd, the Indian arm of the British pharma giant AstraZeneca plc.
This isn’t your typical generic pharma exporter grinding out margins. This is an oncology-heavy, innovation-driven MNC arm that sells blockbuster therapies like cancer drugs — and then charges the market 107 times earnings for the privilege.
Latest quarter (Dec 2025) shows:
- Revenue up 38.9% YoY
- Profit down 42.3% YoY
- Operating margin collapsed to 7%
So sales are sprinting. Margins are gasping.
Is this a temporary blip due to product launches and pricing drama? Or is the premium valuation finally demanding oxygen?
Let’s dissect this Swiss-knife oncology machine.
2. Introduction – Big Daddy Pharma’s Indian Kid
If Indian pharma were a Bollywood film, AstraZeneca India would be the foreign-returned rich cousin.
It doesn’t manufacture low-cost generics at scale like most Indian players. It markets high-value patented therapies in oncology, cardiovascular, respiratory and rare diseases.
Its global parent, AstraZeneca plc, is known for:
- Oncology dominance
- The Oxford-AstraZeneca COVID vaccine
- Aggressive innovation pipelines
The Indian subsidiary:
- Promoter holding: 75%
- Practically debt-free
- High ROCE business
- But trading at 27.9x book value
That valuation screams “innovation premium”.
But here’s the twist.
While revenue has grown at 29% CAGR (3 years), quarterly profits are volatile because this is not a volume game — it’s a product approval game.
One CDSCO nod can change the trajectory.
One NPPA notice can disturb the party.
Are you investing in steady earnings or in regulatory roulette?
Let’s see what exactly they sell.
3. Business Model – WTF Do They Even Do?
Think of AstraZeneca India as a high-end medical weapons distributor.
It doesn’t manufacture at scale anymore — in fact, it surrendered its manufacturing licence (valid till Dec 2027) in September 2025.
Yes. They exited manufacturing.
So what’s left?
Marketing and distributing patented global drugs in India.
Key therapeutic areas:
Oncology (56%
